Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders - PubMed (original) (raw)
Review
Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders
Lauren P McLaughlin et al. Curr Allergy Asthma Rep. 2017 Jan.
Abstract
Primary immunodeficiency disorders (PID) are a group of inborn errors of immunity with a broad range of clinical severity but often associated with recurrent and serious infections. While hematopoietic stem cell transplantation (HSCT) can be curative for some forms of PID, chronic and/or refractory viral infections remain a cause of morbidity and mortality both before and after HSCT. Although antiviral pharmacologic agents exist for many viral pathogens, these are associated with significant costs and toxicities and may not be effective for increasingly drug-resistant pathogens. Thus, the emergence of adoptive immunotherapy with virus-specific T lymphocytes (VSTs) is an attractive option for addressing the underlying impaired T cell immunity in many PID patients. VSTs have been utilized for PID patients following HSCT in many prior phase I trials, and may potentially be beneficial before HSCT in patients with chronic viral infections. We review the various methods of generating VSTs, clinical experience using VSTs for PID patients, and current limitations as well as potential ways to broaden the clinical applicability of adoptive immunotherapy for PID patients.
Keywords: Adoptive immunotherapy; Antiviral therapy; Cytotoxic T lymphocytes; Hematopoietic stem cell transplantation; Primary immunodeficiency.
Conflict of interest statement
Conflict of Interest Drs. McLaughlin, Bollard, and Keller declare no conflicts of interest relevant to this manuscript.
Similar articles
- Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
McLaughlin LP, Bollard CM, Keller MD. McLaughlin LP, et al. Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018. Front Immunol. 2018. PMID: 29616044 Free PMC article. Review. - Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD. Naik S, et al. J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24. J Allergy Clin Immunol. 2016. PMID: 26920464 Free PMC article. - Applications of virus-specific T cell therapies post-BMT.
Motta CM, Keller MD, Bollard CM. Motta CM, et al. Semin Hematol. 2023 Jan;60(1):10-19. doi: 10.1053/j.seminhematol.2022.12.002. Epub 2022 Dec 23. Semin Hematol. 2023. PMID: 37080705 Review. - Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Tzannou I, et al. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7. J Clin Oncol. 2017. PMID: 28783452 Free PMC article. Clinical Trial. - Virus-specific T-cell therapies for patients with primary immune deficiency.
Keller MD, Bollard CM. Keller MD, et al. Blood. 2020 Feb 27;135(9):620-628. doi: 10.1182/blood.2019000924. Blood. 2020. PMID: 31942610 Free PMC article. Review.
Cited by
- Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.
Marciano BE, Holland SM. Marciano BE, et al. Front Immunol. 2017 Aug 9;8:937. doi: 10.3389/fimmu.2017.00937. eCollection 2017. Front Immunol. 2017. PMID: 28848545 Free PMC article. Review. - Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.
Cortese I, Reich DS, Nath A. Cortese I, et al. Nat Rev Neurol. 2021 Jan;17(1):37-51. doi: 10.1038/s41582-020-00427-y. Epub 2020 Nov 20. Nat Rev Neurol. 2021. PMID: 33219338 Free PMC article. Review. - IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells.
Hsieh WC, Hsu TS, Chang YJ, Lai MZ. Hsieh WC, et al. Nat Commun. 2018 Jan 31;9(1):463. doi: 10.1038/s41467-018-02862-4. Nat Commun. 2018. PMID: 29386580 Free PMC article. - The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.
Hont AB, Powell AB, Sohai DK, Valdez IK, Stanojevic M, Geiger AE, Chaudhary K, Dowlati E, Bollard CM, Cruz CRY. Hont AB, et al. Mol Ther. 2022 Jun 1;30(6):2130-2152. doi: 10.1016/j.ymthe.2022.02.002. Epub 2022 Feb 9. Mol Ther. 2022. PMID: 35149193 Free PMC article. Review. - Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
McLaughlin LP, Bollard CM, Keller MD. McLaughlin LP, et al. Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018. Front Immunol. 2018. PMID: 29616044 Free PMC article. Review.
References
- Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015. - PubMed
- Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602–610 e601–611. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources